-
1
-
-
77957010441
-
Targeting tumor-initiating cells to improve the cure rates for triple-negative breast cancer
-
Stratford AL, Reipas K, Maxwell C and Dunn SE. Targeting tumor-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med. 2010; 12:e22.
-
(2010)
Expert Rev Mol Med.
, vol.12
-
-
Stratford, A.L.1
Reipas, K.2
Maxwell, C.3
Dunn, S.E.4
-
2
-
-
41649102048
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
-
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-1281.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.8
, pp. 1275-1281
-
-
Liedtke, C.1
Mazouni, C.2
Hess, K.R.3
Andre, F.4
Tordai, A.5
Mejia, J.A.6
Symmans, W.F.7
Gonzalez-Angulo, A.M.8
Hennessy, B.9
Green, M.10
Cristofanilli, M.11
Hortobagyi, G.N.12
Pusztai, L.13
-
3
-
-
34547661993
-
Triple-negative breast cancer: clinical features and patterns of recurrence
-
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-4434.
-
(2007)
Clin Cancer Res.
, vol.13
, Issue.15 PART 1
, pp. 4429-4434
-
-
Dent, R.1
Trudeau, M.2
Pritchard, K.I.3
Hanna, W.M.4
Kahn, H.K.5
Sawka, C.A.6
Lickley, L.A.7
Rawlinson, E.8
Sun, P.9
Narod, S.A.10
-
4
-
-
84856041070
-
Unraveling the complexity of basal-like breast cancer
-
Marotta LL and Polyak K. Unraveling the complexity of basal-like breast cancer. Oncotarget. 2011; 2(8):588-589.
-
(2011)
Oncotarget.
, vol.2
, Issue.8
, pp. 588-589
-
-
Marotta, L.L.1
Polyak, K.2
-
5
-
-
62649113168
-
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells
-
Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP and Dunn SE. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008; 10(6):R99.
-
(2008)
Breast Cancer Res.
, vol.10
, Issue.6
-
-
Stratford, A.L.1
Fry, C.J.2
Desilets, C.3
Davies, A.H.4
Cho, Y.Y.5
Li, Y.6
Dong, Z.7
Berquin, I.M.8
Roux, P.P.9
Dunn, S.E.10
-
6
-
-
42949169517
-
The RSK factors of activating the Ras/MAPK signaling cascade
-
Carriere A, Ray H, Blenis J and Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci. 2008; 13:4258-4275.
-
(2008)
Front Biosci.
, vol.13
, pp. 4258-4275
-
-
Carriere, A.1
Ray, H.2
Blenis, J.3
Roux, P.P.4
-
7
-
-
80053388827
-
YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention
-
Davies AH and Dunn SE. YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention. Oncotarget. 2011; 2(5):401-406.
-
(2011)
Oncotarget.
, vol.2
, Issue.5
, pp. 401-406
-
-
Davies, A.H.1
Dunn, S.E.2
-
8
-
-
67249107699
-
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility
-
Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA and Slingerland JM. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A. 2009; 106(23):9268-9273.
-
(2009)
Proc Natl Acad Sci U S A.
, vol.106
, Issue.23
, pp. 9268-9273
-
-
Larrea, M.D.1
Hong, F.2
Wander, S.A.3
da Silva, T.G.4
Helfman, D.5
Lannigan, D.6
Smith, J.A.7
Slingerland, J.M.8
-
9
-
-
78649872212
-
A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration
-
Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE and Haber DA. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 2010; 24(23):2654-2665.
-
(2010)
Genes Dev.
, vol.24
, Issue.23
, pp. 2654-2665
-
-
Smolen, G.A.1
Zhang, J.2
Zubrowski, M.J.3
Edelman, E.J.4
Luo, B.5
Yu, M.6
Ng, L.W.7
Scherber, C.M.8
Schott, B.J.9
Ramaswamy, S.10
Irimia, D.11
Root, D.E.12
Haber, D.A.13
-
10
-
-
84862868502
-
Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers
-
Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, Lasham A, Print CG and Dunn SE. Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers. Stem Cells. 2012; 30(7):1338-1348.
-
(2012)
Stem Cells.
, vol.30
, Issue.7
, pp. 1338-1348
-
-
Stratford, A.L.1
Reipas, K.2
Hu, K.3
Fotovati, A.4
Brough, R.5
Frankum, J.6
Takhar, M.7
Watson, P.8
Ashworth, A.9
Lord, C.J.10
Lasham, A.11
Print, C.G.12
Dunn, S.E.13
-
11
-
-
80053465657
-
Functional viability profiles of breast cancer
-
Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, et al. Functional viability profiles of breast cancer. Cancer Discov. 2011; 1(3):260-273.
-
(2011)
Cancer Discov.
, vol.1
, Issue.3
, pp. 260-273
-
-
Brough, R.1
Frankum, J.R.2
Sims, D.3
Mackay, A.4
Mendes-Pereira, A.M.5
Bajrami, I.6
Costa-Cabral, S.7
Rafiq, R.8
Ahmad, A.S.9
Cerone, M.A.10
Natrajan, R.11
Sharpe, R.12
Shiu, K.K.13
Wetterskog, D.14
Dedes, K.J.15
Lambros, M.B.16
-
12
-
-
33646057985
-
Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK
-
Xu YM, Smith JA, Lannigan DA and Hecht SM. Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK. Bioorg Med Chem. 2006; 14(11):3974-3977.
-
(2006)
Bioorg Med Chem.
, vol.14
, Issue.11
, pp. 3974-3977
-
-
Xu, Y.M.1
Smith, J.A.2
Lannigan, D.A.3
Hecht, S.M.4
-
13
-
-
78751482234
-
Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation
-
Liu K, Cho YY, Yao K, Nadas J, Kim DJ, Cho EJ, Lee MH, Pugliese A, Zhang J, Bode AM and Dong Z. Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation. J Biol Chem. 2011; 286(3):2057-2066.
-
(2011)
J Biol Chem.
, vol.286
, Issue.3
, pp. 2057-2066
-
-
Liu, K.1
Cho, Y.Y.2
Yao, K.3
Nadas, J.4
Kim, D.J.5
Cho, E.J.6
Lee, M.H.7
Pugliese, A.8
Zhang, J.9
Bode, A.M.10
Dong, Z.11
-
14
-
-
34249661589
-
Structural basis for the activity of the RSK-specific inhibitor, SL0101
-
Smith JA, Maloney DJ, Hecht SM and Lannigan DA. Structural basis for the activity of the RSK-specific inhibitor, SL0101. Bioorg Med Chem. 2007; 15(14):5018-5034.
-
(2007)
Bioorg Med Chem.
, vol.15
, Issue.14
, pp. 5018-5034
-
-
Smith, J.A.1
Maloney, D.J.2
Hecht, S.M.3
Lannigan, D.A.4
-
15
-
-
79961044176
-
Attenuation of ERK/RSK2-driven NFkappaB gene expression and cancer cell proliferation by kurarinone, a lavandulyl flavanone isolated from Sophora flavescens ait. roots
-
Berghe WV, De Naeyer A, Dijsselbloem N, David JP, De Keukeleire D and Haegeman G. Attenuation of ERK/RSK2-driven NFkappaB gene expression and cancer cell proliferation by kurarinone, a lavandulyl flavanone isolated from Sophora flavescens ait. roots. Endocr Metab Immune Disord Drug Targets. 2011; 11(3):247-261.
-
(2011)
Endocr Metab Immune Disord Drug Targets
, vol.11
, Issue.3
, pp. 247-261
-
-
Berghe, W.V.1
De Naeyer, A.2
Dijsselbloem, N.3
David, J.P.4
De Keukeleire, D.5
Haegeman, G.6
-
16
-
-
59449093709
-
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
-
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D and Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008; 10(5):R86.
-
(2008)
Breast Cancer Res.
, vol.10
, Issue.5
-
-
Habibi, G.1
Leung, S.2
Law, J.H.3
Gelmon, K.4
Masoudi, H.5
Turbin, D.6
Pollak, M.7
Nielsen, T.O.8
Huntsman, D.9
Dunn, S.E.10
-
17
-
-
77950849807
-
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance
-
To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ and Dunn SE. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010; 70(7):2840-2851.
-
(2010)
Cancer Res.
, vol.70
, Issue.7
, pp. 2840-2851
-
-
To, K.1
Fotovati, A.2
Reipas, K.M.3
Law, J.H.4
Hu, K.5
Wang, J.6
Astanehe, A.7
Davies, A.H.8
Lee, L.9
Stratford, A.L.10
Raouf, A.11
Johnson, P.12
Berquin, I.M.13
Royer, H.D.14
Eaves, C.J.15
Dunn, S.E.16
-
18
-
-
44049100934
-
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
-
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-679.
-
(2008)
J Natl Cancer Inst.
, vol.100
, Issue.9
, pp. 672-679
-
-
Li, X.1
Lewis, M.T.2
Huang, J.3
Gutierrez, C.4
Osborne, C.K.5
Wu, M.F.6
Hilsenbeck, S.G.7
Pavlick, A.8
Zhang, X.9
Chamness, G.C.10
Wong, H.11
Rosen, J.12
Chang, J.C.13
-
19
-
-
69549131213
-
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
-
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106(33):13820-13825.
-
(2009)
Proc Natl Acad Sci U S A.
, vol.106
, Issue.33
, pp. 13820-13825
-
-
Creighton, C.J.1
Li, X.2
Landis, M.3
Dixon, J.M.4
Neumeister, V.M.5
Sjolund, A.6
Rimm, D.L.7
Wong, H.8
Rodriguez, A.9
Herschkowitz, J.I.10
Fan, C.11
Zhang, X.12
He, X.13
Pavlick, A.14
Gutierrez, M.C.15
Renshaw, L.16
-
20
-
-
79957608448
-
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
-
Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS and Park SY. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011; 104(11):1730-1738.
-
(2011)
Br J Cancer.
, vol.104
, Issue.11
, pp. 1730-1738
-
-
Lee, H.E.1
Kim, J.H.2
Kim, Y.J.3
Choi, S.Y.4
Kim, S.W.5
Kang, E.6
Chung, I.Y.7
Kim, I.A.8
Kim, E.J.9
Choi, Y.10
Ryu, H.S.11
Park, S.Y.12
-
21
-
-
33845904383
-
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
-
Phillips TM, McBride WH and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-1785.
-
(2006)
J Natl Cancer Inst.
, vol.98
, Issue.24
, pp. 1777-1785
-
-
Phillips, T.M.1
McBride, W.H.2
Pajonk, F.3
-
22
-
-
0037388204
-
Prospective identification of tumorigenic breast cancer cells
-
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-3988.
-
(2003)
Proc Natl Acad Sci U S A.
, vol.100
, Issue.7
, pp. 3983-3988
-
-
Al-Hajj, M.1
Wicha, M.S.2
Benito-Hernandez, A.3
Morrison, S.J.4
Clarke, M.F.5
-
23
-
-
48949119473
-
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
-
Fillmore CM and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10(2):R25.
-
(2008)
Breast Cancer Res.
, vol.10
, Issue.2
-
-
Fillmore, C.M.1
Kuperwasser, C.2
-
24
-
-
76549084826
-
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor
-
Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ and Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010; 70(2):709-718.
-
(2010)
Cancer Res.
, vol.70
, Issue.2
, pp. 709-718
-
-
Harrison, H.1
Farnie, G.2
Howell, S.J.3
Rock, R.E.4
Stylianou, S.5
Brennan, K.R.6
Bundred, N.J.7
Clarke, R.B.8
-
25
-
-
77953163539
-
CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer
-
Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E and Vonderhaar BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010; 70(11):4624-4633.
-
(2010)
Cancer Res.
, vol.70
, Issue.11
, pp. 4624-4633
-
-
Meyer, M.J.1
Fleming, J.M.2
Lin, A.F.3
Hussnain, S.A.4
Ginsburg, E.5
Vonderhaar, B.K.6
-
26
-
-
33750306612
-
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype
-
Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH and Cote RJ. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006; 12(19):5615-5621.
-
(2006)
Clin Cancer Res.
, vol.12
, Issue.19
, pp. 5615-5621
-
-
Balic, M.1
Lin, H.2
Young, L.3
Hawes, D.4
Giuliano, A.5
McNamara, G.6
Datar, R.H.7
Cote, R.J.8
-
27
-
-
33847419142
-
Molecular definition of breast tumor heterogeneity
-
Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11(3):259-273.
-
(2007)
Cancer Cell.
, vol.11
, Issue.3
, pp. 259-273
-
-
Shipitsin, M.1
Campbell, L.L.2
Argani, P.3
Weremowicz, S.4
Bloushtain-Qimron, N.5
Yao, J.6
Nikolskaya, T.7
Serebryiskaya, T.8
Beroukhim, R.9
Hu, M.10
Halushka, M.K.11
Sukumar, S.12
Parker, L.M.13
Anderson, K.S.14
Harris, L.N.15
Garber, J.E.16
-
28
-
-
18944375734
-
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells
-
Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM and Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004; 6(6):R605-615.
-
(2004)
Breast Cancer Res.
, vol.6
, Issue.6
-
-
Dontu, G.1
Jackson, K.W.2
McNicholas, E.3
Kawamura, M.J.4
Abdallah, W.M.5
Wicha, M.S.6
-
29
-
-
48649096223
-
Transcriptome analysis of the normal human mammary cell commitment and differentiation process
-
Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, Iscove N, Jones S, McKinney S, Emerman J, Aparicio S, Marra M and Eaves C. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell. 2008; 3(1):109-118.
-
(2008)
Cell Stem Cell.
, vol.3
, Issue.1
, pp. 109-118
-
-
Raouf, A.1
Zhao, Y.2
To, K.3
Stingl, J.4
Delaney, A.5
Barbara, M.6
Iscove, N.7
Jones, S.8
McKinney, S.9
Emerman, J.10
Aparicio, S.11
Marra, M.12
Eaves, C.13
-
30
-
-
0029871104
-
Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis
-
Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, Callahan R, Merlino G and Smith GH. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 1996; 56(8):1775-1785.
-
(1996)
Cancer Res.
, vol.56
, Issue.8
, pp. 1775-1785
-
-
Gallahan, D.1
Jhappan, C.2
Robinson, G.3
Hennighausen, L.4
Sharp, R.5
Kordon, E.6
Callahan, R.7
Merlino, G.8
Smith, G.H.9
-
31
-
-
34247581697
-
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways
-
Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG and Bundred NJ. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst. 2007; 99(8):616-627.
-
(2007)
J Natl Cancer Inst.
, vol.99
, Issue.8
, pp. 616-627
-
-
Farnie, G.1
Clarke, R.B.2
Spence, K.3
Pinnock, N.4
Brennan, K.5
Anderson, N.G.6
Bundred, N.J.7
-
32
-
-
62649165025
-
Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells
-
Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ and Dunn SE. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene. 2009; 28(11):1421-1431.
-
(2009)
Oncogene.
, vol.28
, Issue.11
, pp. 1421-1431
-
-
Finkbeiner, M.R.1
Astanehe, A.2
To, K.3
Fotovati, A.4
Davies, A.H.5
Zhao, Y.6
Jiang, H.7
Stratford, A.L.8
Shadeo, A.9
Boccaccio, C.10
Comoglio, P.11
Mertens, P.R.12
Eirew, P.13
Raouf, A.14
Eaves, C.J.15
Dunn, S.E.16
-
33
-
-
4344668661
-
Drug repositioning: identifying and developing new uses for existing drugs
-
Ashburn TT and Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-683.
-
(2004)
Nat Rev Drug Discov.
, vol.3
, Issue.8
, pp. 673-683
-
-
Ashburn, T.T.1
Thor, K.B.2
-
34
-
-
58249116704
-
The prince and the pauper. A tale of anticancer targeted agents
-
Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, Medina-Franco JL, Gonzalez-Fierro A and Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer. 2008; 7:82.
-
(2008)
Mol Cancer.
, vol.7
, pp. 82
-
-
Duenas-Gonzalez, A.1
Garcia-Lopez, P.2
Herrera, L.A.3
Medina-Franco, J.L.4
Gonzalez-Fierro, A.5
Candelaria, M.6
-
35
-
-
79961166537
-
Finding promiscuous old drugs for new uses
-
Ekins S and Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res. 2011; 28(8):1785-1791.
-
(2011)
Pharm Res.
, vol.28
, Issue.8
, pp. 1785-1791
-
-
Ekins, S.1
Williams, A.J.2
-
36
-
-
68749099671
-
Identification of selective inhibitors of cancer stem cells by high-throughput screening
-
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659.
-
(2009)
Cell.
, vol.138
, Issue.4
, pp. 645-659
-
-
Gupta, P.B.1
Onder, T.T.2
Jiang, G.3
Tao, K.4
Kuperwasser, C.5
Weinberg, R.A.6
Lander, E.S.7
-
37
-
-
80052026293
-
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions
-
Vazquez-Martin A, Lopez-Bonetc E, Cufi S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat. 2011; 14(4-5):212-223.
-
(2011)
Drug Resist Updat.
, vol.14
, Issue.4-5
, pp. 212-223
-
-
Vazquez-Martin, A.1
Lopez-Bonetc, E.2
Cufi, S.3
Oliveras-Ferraros, C.4
Del Barco, S.5
Martin-Castillo, B.6
Menendez, J.A.7
-
38
-
-
84864536555
-
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
-
Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B and Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012; 3(4):395-398.
-
(2012)
Oncotarget.
, vol.3
, Issue.4
, pp. 395-398
-
-
Cufi, S.1
Corominas-Faja, B.2
Vazquez-Martin, A.3
Oliveras-Ferraros, C.4
Dorca, J.5
Bosch-Barrera, J.6
Martin-Castillo, B.7
Menendez, J.A.8
-
39
-
-
79955490053
-
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types
-
Iliopoulos D, Hirsch HA and Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011; 71(9):3196-3201.
-
(2011)
Cancer Res.
, vol.71
, Issue.9
, pp. 3196-3201
-
-
Iliopoulos, D.1
Hirsch, H.A.2
Struhl, K.3
-
40
-
-
79955805229
-
Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties
-
Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL and Wang W. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011; 104(10):1564-1574.
-
(2011)
Br J Cancer.
, vol.104
, Issue.10
, pp. 1564-1574
-
-
Yip, N.C.1
Fombon, I.S.2
Liu, P.3
Brown, S.4
Kannappan, V.5
Armesilla, A.L.6
Xu, B.7
Cassidy, J.8
Darling, J.L.9
Wang, W.10
-
41
-
-
77958556510
-
Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability
-
Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ and Dunn SE. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One. 2010; 5(9).
-
(2010)
PLoS One.
, vol.5
, Issue.9
-
-
Law, J.H.1
Li, Y.2
To, K.3
Wang, M.4
Astanehe, A.5
Lambie, K.6
Dhillon, J.7
Jones, S.J.8
Gleave, M.E.9
Eaves, C.J.10
Dunn, S.E.11
-
42
-
-
67650097331
-
Comparison of several molecular docking programs: pose prediction and virtual screening accuracy
-
Cross JB, Thompson DC, Rai BK, Baber JC, Fan KY, Hu Y and Humblet C. Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. J Chem Inf Model. 2009; 49(6):1455-1474.
-
(2009)
J Chem Inf Model.
, vol.49
, Issue.6
, pp. 1455-1474
-
-
Cross, J.B.1
Thompson, D.C.2
Rai, B.K.3
Baber, J.C.4
Fan, K.Y.5
Hu, Y.6
Humblet, C.7
-
43
-
-
33244483907
-
On evaluating molecular-docking methods for pose prediction and enrichment factors
-
Chen H, Lyne PD, Giordanetto F, Lovell T and Li J. On evaluating molecular-docking methods for pose prediction and enrichment factors. J Chem Inf Model. 2006; 46(1):401-415.
-
(2006)
J Chem Inf Model.
, vol.46
, Issue.1
, pp. 401-415
-
-
Chen, H.1
Lyne, P.D.2
Giordanetto, F.3
Lovell, T.4
Li, J.5
-
44
-
-
84864214802
-
RSK2 Binding Models Delineate Key Features for Activity
-
Gussio R, Currens MJ, Scudiero DA, Smith JA, Lannigan DA, Shoemaker RH, Zaharevitz DW and Nguyen TL. RSK2 Binding Models Delineate Key Features for Activity. J Chem Pharm Res. 2010; 2(5):587-598.
-
(2010)
J Chem Pharm Res.
, vol.2
, Issue.5
, pp. 587-598
-
-
Gussio, R.1
Currens, M.J.2
Scudiero, D.A.3
Smith, J.A.4
Lannigan, D.A.5
Shoemaker, R.H.6
Zaharevitz, D.W.7
Nguyen, T.L.8
-
45
-
-
33846312875
-
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
-
Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P and Alessi DR. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007; 401(1):29-38.
-
(2007)
Biochem J.
, vol.401
, Issue.1
, pp. 29-38
-
-
Sapkota, G.P.1
Cummings, L.2
Newell, F.S.3
Armstrong, C.4
Bain, J.5
Frodin, M.6
Grauert, M.7
Hoffmann, M.8
Schnapp, G.9
Steegmaier, M.10
Cohen, P.11
Alessi, D.R.12
-
46
-
-
0036400016
-
Dietary flavonoids: bioavailability, metabolic effects, and safety
-
Ross JA and Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002; 22:19-34.
-
(2002)
Annu Rev Nutr.
, vol.22
, pp. 19-34
-
-
Ross, J.A.1
Kasum, C.M.2
-
47
-
-
55449124465
-
Luteolin, a flavonoid with potential for cancer prevention and therapy
-
Lin Y, Shi R, Wang X and Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008; 8(7):634-646.
-
(2008)
Curr Cancer Drug Targets.
, vol.8
, Issue.7
, pp. 634-646
-
-
Lin, Y.1
Shi, R.2
Wang, X.3
Shen, H.M.4
-
48
-
-
62749165351
-
Distribution and biological activities of the flavonoid luteolin
-
Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009; 9(1):31-59.
-
(2009)
Mini Rev Med Chem.
, vol.9
, Issue.1
, pp. 31-59
-
-
Lopez-Lazaro, M.1
-
49
-
-
44449122711
-
Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line
-
Wu B, Zhang Q, Shen W and Zhu J. Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol Cell Biochem. 2008; 313(1-2):125-132.
-
(2008)
Mol Cell Biochem.
, vol.313
, Issue.1-2
, pp. 125-132
-
-
Wu, B.1
Zhang, Q.2
Shen, W.3
Zhu, J.4
-
50
-
-
44749083055
-
Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells
-
Du GJ, Song ZH, Lin HH, Han XF, Zhang S and Yang YM. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells. Biochem Biophys Res Commun. 2008; 372(3):497-502.
-
(2008)
Biochem Biophys Res Commun.
, vol.372
, Issue.3
, pp. 497-502
-
-
Du, G.J.1
Song, Z.H.2
Lin, H.H.3
Han, X.F.4
Zhang, S.5
Yang, Y.M.6
-
51
-
-
0036835460
-
Integration of virtual and high-throughput screening
-
Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 2002; 1(11):882-894.
-
(2002)
Nat Rev Drug Discov.
, vol.1
, Issue.11
, pp. 882-894
-
-
Bajorath, J.1
-
52
-
-
78650206189
-
The promise and challenges of targeting RSK for the treatment of cancer
-
Stratford AL and Dunn SE. The promise and challenges of targeting RSK for the treatment of cancer. Expert Opin Ther Targets. 2011; 15(1):1-4.
-
(2011)
Expert Opin Ther Targets.
, vol.15
, Issue.1
, pp. 1-4
-
-
Stratford, A.L.1
Dunn, S.E.2
-
53
-
-
78650183595
-
Targeting RSK2 in human malignancies
-
Kang S and Chen J. Targeting RSK2 in human malignancies. Expert Opin Ther Targets. 2011; 15(1):11-20.
-
(2011)
Expert Opin Ther Targets.
, vol.15
, Issue.1
, pp. 11-20
-
-
Kang, S.1
Chen, J.2
-
54
-
-
0033855919
-
The therapeutic potential of flavonoids
-
Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs. 2000; 9(9):2103-2119.
-
(2000)
Expert Opin Investig Drugs.
, vol.9
, Issue.9
, pp. 2103-2119
-
-
Wang, H.K.1
-
55
-
-
34247512973
-
A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells
-
Ju W, Wang X, Shi H, Chen W, Belinsky SA and Lin Y. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol. 2007; 71(5):1381-1388.
-
(2007)
Mol Pharmacol.
, vol.71
, Issue.5
, pp. 1381-1388
-
-
Ju, W.1
Wang, X.2
Shi, H.3
Chen, W.4
Belinsky, S.A.5
Lin, Y.6
-
56
-
-
36148988399
-
Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages
-
Chen CY, Peng WH, Tsai KD and Hsu SL. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 2007; 81(23-24):1602-1614.
-
(2007)
Life Sci.
, vol.81
, Issue.23-24
, pp. 1602-1614
-
-
Chen, C.Y.1
Peng, W.H.2
Tsai, K.D.3
Hsu, S.L.4
-
57
-
-
84555189440
-
Regulation and function of the RSK family of protein kinases
-
Romeo Y, Zhang X and Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012; 441(2):553-569.
-
(2012)
Biochem J.
, vol.441
, Issue.2
, pp. 553-569
-
-
Romeo, Y.1
Zhang, X.2
Roux, P.P.3
-
58
-
-
68349130357
-
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
-
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009; 15(8):907-913.
-
(2009)
Nat Med.
, vol.15
, Issue.8
, pp. 907-913
-
-
Lim, E.1
Vaillant, F.2
Wu, D.3
Forrest, N.C.4
Pal, B.5
Hart, A.H.6
Asselin-Labat, M.L.7
Gyorki, D.E.8
Ward, T.9
Partanen, A.10
Feleppa, F.11
Huschtscha, L.I.12
Thorne, H.J.13
Fox, S.B.14
Yan, M.15
French, J.D.16
-
59
-
-
4143150688
-
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
-
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16):5367-5374.
-
(2004)
Clin Cancer Res.
, vol.10
, Issue.16
, pp. 5367-5374
-
-
Nielsen, T.O.1
Hsu, F.D.2
Jensen, K.3
Cheang, M.4
Karaca, G.5
Hu, Z.6
Hernandez-Boussard, T.7
Livasy, C.8
Cowan, D.9
Dressler, L.10
Akslen, L.A.11
Ragaz, J.12
Gown, A.M.13
Gilks, C.B.14
van de Rijn, M.15
Perou, C.M.16
-
60
-
-
78649512128
-
The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells
-
Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K and Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010; 29(47):6294-6300.
-
(2010)
Oncogene.
, vol.29
, Issue.47
, pp. 6294-6300
-
-
Dhillon, J.1
Astanehe, A.2
Lee, C.3
Fotovati, A.4
Hu, K.5
Dunn, S.E.6
-
61
-
-
34548833559
-
Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth
-
O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, Leon R, Toher J, Mouta-Bellum C, Friesel RE and Liaw L. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol. 2007; 171(3):1023-1036.
-
(2007)
Am J Pathol.
, vol.171
, Issue.3
, pp. 1023-1036
-
-
O'Neill, C.F.1
Urs, S.2
Cinelli, C.3
Lincoln, A.4
Nadeau, R.J.5
Leon, R.6
Toher, J.7
Mouta-Bellum, C.8
Friesel, R.E.9
Liaw, L.10
-
62
-
-
84855344803
-
Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer
-
Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, Ware C, Majumder PK and Hassell JA. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2012; 31(1):93-103.
-
(2012)
Oncogene.
, vol.31
, Issue.1
, pp. 93-103
-
-
Kondratyev, M.1
Kreso, A.2
Hallett, R.M.3
Girgis-Gabardo, A.4
Barcelon, M.E.5
Ilieva, D.6
Ware, C.7
Majumder, P.K.8
Hassell, J.A.9
-
63
-
-
12144289984
-
Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
-
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P and Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7):1739-1749.
-
(2004)
J Med Chem.
, vol.47
, Issue.7
, pp. 1739-1749
-
-
Friesner, R.A.1
Banks, J.L.2
Murphy, R.B.3
Halgren, T.A.4
Klicic, J.J.5
Mainz, D.T.6
Repasky, M.P.7
Knoll, E.H.8
Shelley, M.9
Perry, J.K.10
Shaw, D.E.11
Francis, P.12
Shenkin, P.S.13
-
64
-
-
1642310340
-
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
-
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT and Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004; 47(7):1750-1759.
-
(2004)
J Med Chem.
, vol.47
, Issue.7
, pp. 1750-1759
-
-
Halgren, T.A.1
Murphy, R.B.2
Friesner, R.A.3
Beard, H.S.4
Frye, L.L.5
Pollard, W.T.6
Banks, J.L.7
-
65
-
-
57749089652
-
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival
-
Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M and Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008; 68(24):10238-10246.
-
(2008)
Cancer Res.
, vol.68
, Issue.24
, pp. 10238-10246
-
-
Law, J.H.1
Habibi, G.2
Hu, K.3
Masoudi, H.4
Wang, M.Y.5
Stratford, A.L.6
Park, E.7
Gee, J.M.8
Finlay, P.9
Jones, H.E.10
Nicholson, R.I.11
Carboni, J.12
Gottardis, M.13
Pollak, M.14
Dunn, S.E.15
-
66
-
-
20544455061
-
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells
-
Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005; 24(26):4281-4292.
-
(2005)
Oncogene.
, vol.24
, Issue.26
, pp. 4281-4292
-
-
Sutherland, B.W.1
Kucab, J.2
Wu, J.3
Lee, C.4
Cheang, M.C.5
Yorida, E.6
Turbin, D.7
Dedhar, S.8
Nelson, C.9
Pollak, M.10
Leighton Grimes, H.11
Miller, K.12
Badve, S.13
Huntsman, D.14
Blake-Gilks, C.15
Chen, M.16
|